Fresenius SE & Co. (OTCMKTS:FSNUY) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Fresenius SE & Co. (OTCMKTS:FSNUY) posted its earnings results on Wednesday. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.23 by $0.02, Zacks reports. The company had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.52 billion. Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%.

Fresenius SE & Co. Stock Performance

Shares of Fresenius SE & Co. stock traded up $0.93 during mid-day trading on Thursday, hitting $14.53. 61,073 shares of the stock were exchanged, compared to its average volume of 167,985. Fresenius SE & Co. has a 12 month low of $10.33 and a 12 month high of $17.60. The company has a 50-day simple moving average of $12.91 and a 200 day simple moving average of $12.86. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28. The company has a market capitalization of $32.74 billion, a P/E ratio of 18.39 and a beta of 0.63.

Analysts Set New Price Targets

Several brokerages recently issued reports on FSNUY. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Citigroup restated a “buy” rating on shares of Fresenius SE & Co. in a research note on Wednesday, October 28th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating. According to data from MarketBeat.com, the company has an average rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a Germany-based global health care group that develops and provides products, services and technologies for hospitals, clinics and patients. The company’s activities are focused primarily on health care products and therapies, as well as the operation of hospitals and other medical facilities.

Fresenius Kabi, one of the company’s core businesses, supplies medicines and therapies for critically and chronically ill patients, including intravenous drugs, clinical nutrition, infusion therapies, medical devices and related services.